Denali Therapeutics (NASDAQ:DNLI) Shares Down 5.7% – Here’s Why

Denali Therapeutics Inc. (NASDAQ:DNLI)’s share price was down 5.7% during mid-day trading on Thursday . The stock traded as low as $21.12 and last traded at $21.1850. Approximately 474,514 shares were traded during trading, a decline of 72% from the average daily volume of 1,719,490 shares. The stock had previously closed at $22.47.

Key Denali Therapeutics News

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: FDA approval of AVLAYAH — AVLAYAH received FDA approval as a brain‑targeting therapy for Hunter syndrome, giving Denali its first approved commercial asset and creating a clear commercialization pathway. Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up
• Positive Sentiment: Morgan Stanley raised its price target to $42 and kept an overweight rating — a large revision implying ~131% upside vs. the current price, signaling strong sell‑side confidence post‑approval. Benzinga
• Positive Sentiment: Goldman Sachs raised its target to $40 and reiterated a buy — another high target reflecting elevated expectations for AVLAYAH’s commercial prospects. Benzinga
• Positive Sentiment: Stifel, BTIG, HC Wainwright, Robert W. Baird also raised targets and/or ratings — most moved targets into the $32–$42 range and maintained buy/outperform views, adding upward pressure on the stock. (Sources include Benzinga and TickerReport.) Benzinga TickerReport
• Neutral Sentiment: Company discussion/transcript on commercial launch plans — management provided details on launch timing, supply and go‑to‑market strategy in a call/transcript, helping investors assess execution risk but not immediately changing fundamentals. Denali Discusses FDA Approval and Commercial Launch Plans for AVLAYAH (Transcript)
• Neutral Sentiment: Wider media coverage — outlets (MSN, Business Insider, Seeking Alpha) reported the FDA approval and will likely broaden investor and clinician awareness; coverage supports sentiment but execution and uptake remain the next items to watch. MSN Business Insider

Analyst Ratings Changes

A number of research firms have recently weighed in on DNLI. HC Wainwright boosted their price objective on shares of Denali Therapeutics from $32.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday. Robert W. Baird raised their target price on shares of Denali Therapeutics from $29.00 to $32.00 and gave the stock an “outperform” rating in a research report on Thursday. UBS Group started coverage on shares of Denali Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating for the company. Jefferies Financial Group reiterated a “buy” rating and issued a $40.00 price target on shares of Denali Therapeutics in a report on Monday, March 2nd. Finally, Wolfe Research started coverage on Denali Therapeutics in a research note on Monday, February 23rd. They set a “peer perform” rating on the stock. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $34.82.

Denali Therapeutics Stock Performance

The company has a market cap of $2.88 billion, a price-to-earnings ratio of -6.11 and a beta of 1.02. The company has a current ratio of 9.16, a quick ratio of 9.16 and a debt-to-equity ratio of 0.01. The stock’s 50 day moving average price is $20.43 and its 200 day moving average price is $17.83.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.02. During the same quarter last year, the firm earned ($0.67) earnings per share. On average, analysts expect that Denali Therapeutics Inc. will post -2.71 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Alexander O. Schuth sold 17,218 shares of the company’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $284,097.00. Following the completion of the sale, the insider directly owned 282,828 shares in the company, valued at $4,666,662. This represents a 5.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Ryan J. Watts sold 35,198 shares of the stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total value of $580,767.00. Following the completion of the transaction, the chief executive officer directly owned 296,833 shares in the company, valued at $4,897,744.50. This trade represents a 10.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 12.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Denali Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of Denali Therapeutics in the 4th quarter valued at about $84,525,000. Holocene Advisors LP increased its position in Denali Therapeutics by 677.8% during the 3rd quarter. Holocene Advisors LP now owns 3,135,712 shares of the company’s stock worth $45,531,000 after purchasing an additional 2,732,540 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Denali Therapeutics by 77.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 3,835,803 shares of the company’s stock valued at $63,329,000 after buying an additional 1,672,098 shares during the period. Temasek Holdings Private Ltd raised its holdings in Denali Therapeutics by 30.9% in the fourth quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company’s stock valued at $115,784,000 after buying an additional 1,657,142 shares during the period. Finally, T. Rowe Price Investment Management Inc. lifted its position in Denali Therapeutics by 28.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 7,254,132 shares of the company’s stock valued at $119,766,000 after buying an additional 1,615,565 shares in the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.